Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

Michiel C. Verboom*, Jacqueline S.L. Kloth, Jesse J. Swen, Stefan Sleijfer, Anna K.L. Reyners, Neeltje Steeghs, Ron H.J. Mathijssen, Hans Gelderblom, Henk Jan Guchelaar

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Neuroscience